1284 related articles for article (PubMed ID: 26075522)
21. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
[TBL] [Abstract][Full Text] [Related]
22. Proteolysis-targeting chimeras mediate the degradation of bromodomain and extra-terminal domain proteins.
Yang Y; Wu Z; Chen P; Zheng P; Zhang H; Zhou J
Future Med Chem; 2020 Sep; 12(18):1669-1683. PubMed ID: 32893690
[TBL] [Abstract][Full Text] [Related]
23. Preclinical Studies of PROTACs in Hematological Malignancies.
Fuchs O; Bokorova R
Cardiovasc Hematol Disord Drug Targets; 2021; 21(1):7-22. PubMed ID: 33687890
[TBL] [Abstract][Full Text] [Related]
24. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
25. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs.
Maneiro M; De Vita E; Conole D; Kounde CS; Zhang Q; Tate EW
Prog Med Chem; 2021; 60():67-190. PubMed ID: 34147206
[TBL] [Abstract][Full Text] [Related]
26. PROTACs: A novel strategy for cancer therapy.
Liu J; Ma J; Liu Y; Xia J; Li Y; Wang ZP; Wei W
Semin Cancer Biol; 2020 Dec; 67(Pt 2):171-179. PubMed ID: 32058059
[TBL] [Abstract][Full Text] [Related]
27. Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin-proteasome pathway.
Ohoka N; Nagai K; Hattori T; Okuhira K; Shibata N; Cho N; Naito M
Cell Death Dis; 2014 Nov; 5(11):e1513. PubMed ID: 25375378
[TBL] [Abstract][Full Text] [Related]
28. Chemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets.
Moon S; Lee BH
Mol Cells; 2018 Nov; 41(11):933-942. PubMed ID: 30486612
[TBL] [Abstract][Full Text] [Related]
29. Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1.
Crew AP; Raina K; Dong H; Qian Y; Wang J; Vigil D; Serebrenik YV; Hamman BD; Morgan A; Ferraro C; Siu K; Neklesa TK; Winkler JD; Coleman KG; Crews CM
J Med Chem; 2018 Jan; 61(2):583-598. PubMed ID: 28692295
[TBL] [Abstract][Full Text] [Related]
30. Protein degradation: a validated therapeutic strategy with exciting prospects.
Lebraud H; Heightman TD
Essays Biochem; 2017 Nov; 61(5):517-527. PubMed ID: 28970340
[TBL] [Abstract][Full Text] [Related]
31. PROTAC-DB: an online database of PROTACs.
Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs).
Tomaselli D; Mautone N; Mai A; Rotili D
Eur J Med Chem; 2020 Dec; 207():112750. PubMed ID: 32871345
[TBL] [Abstract][Full Text] [Related]
33. New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation.
Wang X; Feng S; Fan J; Li X; Wen Q; Luo N
Biochem Pharmacol; 2016 Sep; 116():200-9. PubMed ID: 27473774
[TBL] [Abstract][Full Text] [Related]
34. The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents.
Coll-Martínez B; Delgado A; Crosas B
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339292
[TBL] [Abstract][Full Text] [Related]
35. PROTAC-mediated crosstalk between E3 ligases.
Steinebach C; Kehm H; Lindner S; Vu LP; Köpff S; López Mármol Á; Weiler C; Wagner KG; Reichenzeller M; Krönke J; Gütschow M
Chem Commun (Camb); 2019 Feb; 55(12):1821-1824. PubMed ID: 30672516
[TBL] [Abstract][Full Text] [Related]
36. Molecular Design, Synthesis, and Evaluation of SNIPER(ER) That Induces Proteasomal Degradation of ERα.
Okuhira K; Demizu Y; Hattori T; Ohoka N; Shibata N; Kurihara M; Naito M
Methods Mol Biol; 2016; 1366():549-560. PubMed ID: 26585163
[TBL] [Abstract][Full Text] [Related]
37. Development of Stabilized Peptide-Based PROTACs against Estrogen Receptor α.
Jiang Y; Deng Q; Zhao H; Xie M; Chen L; Yin F; Qin X; Zheng W; Zhao Y; Li Z
ACS Chem Biol; 2018 Mar; 13(3):628-635. PubMed ID: 29271628
[TBL] [Abstract][Full Text] [Related]
38. Development of cell-permeable peptide-based PROTACs targeting estrogen receptor α.
Dai Y; Yue N; Gong J; Liu C; Li Q; Zhou J; Huang W; Qian H
Eur J Med Chem; 2020 Feb; 187():111967. PubMed ID: 31865016
[TBL] [Abstract][Full Text] [Related]
39. Targeted protein degradation by PROTACs.
Neklesa TK; Winkler JD; Crews CM
Pharmacol Ther; 2017 Jun; 174():138-144. PubMed ID: 28223226
[TBL] [Abstract][Full Text] [Related]
40. Targeted Protein Degradation: from Chemical Biology to Drug Discovery.
Cromm PM; Crews CM
Cell Chem Biol; 2017 Sep; 24(9):1181-1190. PubMed ID: 28648379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
